Economic modeling to evaluate the impact of chronic myeloid leukemia therapy management on the oncology care model in the US-Reference-Cited by-同舟云学术

Economic modeling to evaluate the impact of chronic myeloid leukemia therapy management on the oncology care model in the US

Published:2019-05-31 Issue:11 Volume:22 Page:1113-1118
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Jabbour Elias J.¹,Mendiola Martin F.²,Lingohr-Smith Melissa³,Lin Jay³,Makenbaeva Dinara²

Affiliation:

1. The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

2. Bristol-Myers Squibb, Princeton, NJ, USA;

3. Novosys Health, Green Brook, NJ, USA

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://tandfonline.com/doi/pdf/10.1080/13696998.2019.1618316

Reference37 articles.

1. Centers for Medicare & Medicaid Services. Oncology Care Model (OCM). Baltimore, MD [updated 2018 August 8

2. cited 2019 Mar 4]. Available from: https://innovation.cms.gov/initiatives/Oncology-Care/.

3. Centers for Medicare & Medicaid Services. Oncology Care Model (OCM) overview and application process. Baltimore, MD [updated 2015 Feb 19

4. cited 2019 Mar 4]. Available from: https://innovation.cms.gov/resources/OCMintro.html.

5. Centers for Medicare & Medicaid Services. First annual report from the evaluation of the Oncology Care Model: Baseline period. Abt Associates. Bethesda, MD [updated 2018 Feb 1]. Available from: https://downloads.cms.gov/files/cmmi/ocm-baselinereport.pdf.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Distribution of BCR::ABL1 Transcripts in the Different Clinical Phases of Chronic Myeloid Leukemia: Effect on Hematological Parameters and Patient Survival;Genes;2024-04-28

2. Maximizing the Value of Chronic Myeloid Leukemia Management Using Tyrosine Kinase Inhibitors in the USA: Potential Determinants and Consequences of Healthcare Resource Utilization and Costs, with Proposed Optimization Approaches;Clinical Drug Investigation;2024-01-05

3. A Systematic Literature Review of the Economic Evaluations of Treatments for Patients with Chronic Myeloid Leukemia;PharmacoEconomics;2022-09-30

4. Determination of the Cut-off Value for Imatinib Plasma Levels Linked to Occurrence of Bone Pain in CML Patients;Drug Design, Development and Therapy;2022-05

5. Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs;Blood Advances;2021-09-03